Novavax Inc (WBO:NVAX)
€ 9.276 -0.09 (-0.96%) Market Cap: 1.49 Bil Enterprise Value: 734.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 47/100

Novavax Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 08:00PM GMT
Vernon Tolentino Bernardino
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

Hi, everyone. Thanks for coming to the H.C. Wainwright Global Healthcare Conference. My name is Vernon Bernardino. I'm a senior analyst at H.C. Wainwright.

From the Novavax today, we have the privilege of having a discussion with Chief Scientific Officer, Gregor Glenn; and Chief Business Officer and Chief Commercial Officer, John Trizzino.

I think with them today, you'll get a flavor for why this is a company that's on the cusp of emerging as a true vaccine business and one that's perhaps going to be an important player that's going to grow very quickly, very soon.

So before we get -- gets into an overview of the company. Just wondering if you could go over what makes your technology -- your vaccine technology, unique and how it's different from the others out there.

Gregory M. Glenn
Novavax, Inc. - President of Research & Development

Good. Well, thanks for having us. It's great to be here. So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot